Natural Products for the Treatment of Autoimmune Arthritis: Their Mechanisms of Action, Targeted Delivery, and Interplay with the Host Microbiome
- PMID: 30149545
- PMCID: PMC6164747
- DOI: 10.3390/ijms19092508
Natural Products for the Treatment of Autoimmune Arthritis: Their Mechanisms of Action, Targeted Delivery, and Interplay with the Host Microbiome
Abstract
Rheumatoid arthritis (RA) is a chronic, debilitating illness characterized by painful swelling of the joints, inflammation of the synovial lining of the joints, and damage to cartilage and bone. Several anti-inflammatory and disease-modifying drugs are available for RA therapy. However, the prolonged use of these drugs is associated with severe side effects. Furthermore, these drugs are effective only in a proportion of RA patients. Hence, there is a need to search for new therapeutic agents that are effective yet safe. Interestingly, a variety of herbs and other natural products offer a vast resource for such anti-arthritic agents. We discuss here the basic features of RA pathogenesis; the commonly used animal models of RA; the mainstream drugs used for RA; the use of well-characterized natural products possessing anti-arthritic activity; the application of nanoparticles for efficient delivery of such products; and the interplay between dietary products and the host microbiome for maintenance of health and disease induction. We believe that with several advances in the past decade in the characterization and functional studies of natural products, the stage is set for widespread clinical testing and/or use of these products for the treatment of RA and other diseases.
Keywords: EGCG; Tripterygium wilfordii; adjuvant-induced arthritis; arthritis; celastrol; curcumin; dietary supplements; green tea; inflammation; liposomes; microbiome; nanoparticles; natural products; resveratrol; rheumatoid arthritis; targeted delivery; traditional medicine; triptolide.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
-
- Du Montcel S.T., Michou L., Petit-Teixeira E., Osorio J., Lemaire I., Lasbleiz S., Pierlot C., Quillet P., Bardin T., Prum B., et al. New classification of HLA-DRB1 alleles supports the shared epitope hypothesis of rheumatoid arthritis susceptibility. Arthritis Rheumatol. 2005;52:1063–1068. doi: 10.1002/art.20989. - DOI - PubMed
-
- Makrygiannakis D., Hermansson M., Ulfgren A.K., Nicholas A.P., Zendman A.J., Eklund A., Grunewald J., Skold C.M., Klareskog L., Catrina A.I. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann. Rheum. Dis. 2008;67:1488–1492. doi: 10.1136/ard.2007.075192. - DOI - PubMed
-
- Snir O., Widhe M., von Spee C., Lindberg J., Padyukov L., Lundberg K., Engstrom A., Venables P.J., Lundeberg J., Holmdahl R., et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: Association with HLA-DRB1 alleles. Ann. Rheum. Dis. 2009;68:736–743. doi: 10.1136/ard.2008.091355. - DOI - PubMed
-
- Van der Helm-van Mil A.H., Verpoort K.N., Breedveld F.C., Huizinga T.W., Toes R.E., de Vries R.R. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheumatol. 2006;54:1117–1121. doi: 10.1002/art.21739. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous
